Miguel Islas-Ohlmayer, MD
Hematology & Oncology · Edgewood, KYNPI 1295917425
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $73,352 of the $103,160 with a category attached, or 71.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 19.1%. Among hematology & oncology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $526.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$20K
- Novartis$15K
- Jazz Pharmaceuticals Inc.$11K
- ADC Therapeutics America, Inc.$10K
- AbbVie$8K
- Syndax Pharmaceuticals, Inc.$7K
- plus $32K from 28 others
Across 403 payments — averaging $3656.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$470K
- Bristol Myers Squibb$227K
- Pfizer$136K
- Genentech, Inc.$124K
- Incyte Corporation$122K
- Novartis$111K
- plus $285K from 10 others
What the payments were for
- Consulting fees$73,35271%
- Speaking & faculty fees$15,69015%
- Travel & lodging$8,7108%
- Food & beverage$4,8225%
- Education$5871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 32 | $19,680 |
| Novartis | 20 | $15,467 |
| Jazz Pharmaceuticals Inc. | 22 | $11,163 |
| ADC Therapeutics America, Inc. | 7 | $10,278 |
| AbbVie | 14 | $7,777 |
| Syndax Pharmaceuticals, Inc. | 8 | $7,287 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,041 |
| Gilead | 10 | $6,911 |
| Incyte Corporation | 4 | $3,865 |
| Sobi, Inc | 2 | $3,204 |
| Epizyme, Inc. | 2 | $1,875 |
| CTI Biopharma Corp. | 1 | $1,725 |
| AstraZeneca | 2 | $1,408 |
| Janssen Scientific Affairs, LLC | 1 | $1,363 |
| Seagen Inc. | 3 | $1,254 |
| Bristol Myers Squibb | 4 | $933 |
| Beigene, Ltd. | 1 | $525 |
| Johnson & Johnson(2 entities) | 19 | $269 |
| Karyopharm Therapeutics Inc. | 2 | $217 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $165 |
| National Marrow Donor Program | 1 | $163 |
| Amgen | 9 | $150 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Astellas Pharma US Inc | 4 | $72 |
| GSK | 2 | $41 |
| Sanofi | 2 | $40 |
| Aurobindo Pharma USA, Inc. | 2 | $37 |
| Genentech USA, Inc. | 3 | $34 |
| Verastem, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Global Blood Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,160 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 40 | $747,594 |
| Lenalidomide | 41 | $542,830 |
| RevlimidLenalidomide | 21 | $474,543 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $305,222 |
| RezurockBelumosudil Mesylate | 12 | $214,924 |
| ImbruvicaIbrutinib | 13 | $212,751 |
| TasignaNilotinib Hcl | 12 | $106,348 |
| VenclextaVenetoclax | 24 | $97,286 |
| EliquisApixaban | 25 | $19,519 |
| ValacyclovirValacyclovir Hcl | 75 | $2,856 |
| Levofloxacin | 42 | $1,188 |
| Fluconazole | 44 | $1,129 |
| Dexamethasone | 56 | $849 |
| Acyclovir | 39 | $731 |
| Prochlorperazine Maleate | 32 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $7,041 | $747,59440 claims |
| Bristol Myers SquibbRevlimid | $933 | $474,54321 claims |
| GSKOjjaara | $41 | $305,22211 claims |
| Sanofi-aventis U.S. LLCRezurock | $121 | $214,92412 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $165 | $212,75113 claims |
| NovartisTasigna | $15,467 | $106,34812 claims |
| AbbVieVenclexta | $7,777 | $97,28624 claims |
| PfizerEliquis | $20 | $19,51925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Edgewood
- Colleen DarnellEdgewood$7K
- Firas BadinLexington$1.6M
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Nicola JabbourLexington$563K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.